3 hours Inozyme Pharma (NASDAQ:INZY) Earns Outperform Rating from Wedbush MarketBeat
Wedbush reissued an “outperform” rating and set a $15.00 price objective on shares of Inozyme Pharma in a research report on Monday.
Wedbush reissued an “outperform” rating and set a $15.00 price objective on shares of Inozyme Pharma in a research report on Monday.